GW Pharma (GWPH) Posts Q3 Loss of 6c/Share; THCV Phase 2 Missed Primary Endpoint in T2D
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress
August 9, 2016 7:01 AM EDT- Positive Phase 3 Epidiolex pivotal trial in Lennox-Gastaut Syndrome (LGS) - - Positive FDA pre-NDA meeting - NDA for Dravet syndrome and LGS on track for H1 2017 submission - Â Â Â Â Â Â Â Â Â Â Â Â -Conference call today at 8:30 a.m. EDT, 1:30 p.m. BST -
LONDON, Aug. 09, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH) (AIM: GWP) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced... More
